Clinical Trial Update: Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update comparing AKYNZEO (netupitant/palonosetron) with standard of care (including EMEND) for preventing chemotherapy-induced nausea and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Akynzeo (netupitant/palonosetron)
• EMEND (aprepitant)

Snippet

Sponsor: VIFORFRANCE | Conditions: Oncology | Phase 4 | Status: UNKNOWN